Skip to main content
. 2017 Jan 11;13(3):1247–1255. doi: 10.3892/ol.2017.5586

Figure 3.

Figure 3.

Differences in CA19-9, overall survival and effect of insulin therapy between pancreatic cancer patients with and without T2D. (A) Differences in CA19-9 cancer biomarker profile; (B) differences in overall survival; (C) differences in the incidence of pancreatic cancer in T2D patients with and without insulin therapy. CA19-9, carbohydrate antigen 19–9; T2D, type 2 diabetes mellitus.